Profile data is unavailable for this security.
About the company
Frontier Biotechnologies Inc is a China-based company engaged in research and development, production and sales of innovative drugs. The Company's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The Company conducts its businesses within the China market and to overseas markets.
- Revenue in CNY (TTM)126.99m
- Net income in CNY-308.96m
- Incorporated2013
- Employees395.00
- LocationFrontier Biotechnologies IncHi-Tech Park, Jiangning DistrictNANJING 211199ChinaCHN
- Phone+86 2 569648375
- Fax+86 2 569748373
- Websitehttp://www.frontierbiotech.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frontier Biotechnologies Inc | 126.99m | -308.96m | 2.40bn | 395.00 | -- | 1.86 | -- | 18.88 | -0.8248 | -0.8248 | 0.339 | 3.44 | 0.0575 | 1.40 | 3.00 | 321,484.60 | -13.99 | -14.05 | -16.25 | -15.78 | 30.10 | 2.35 | -243.30 | -450.08 | 2.86 | -- | 0.2347 | -- | 34.82 | 126.63 | 7.79 | -- | 28.13 | -- |
| Hanshang Group Co Ltd | 1.36bn | 49.62m | 2.45bn | 2.38k | 48.74 | 1.42 | -- | 1.80 | 0.1707 | 0.1707 | 4.65 | 5.84 | 0.3705 | 2.75 | 8.35 | 573,421.20 | 1.16 | 2.00 | 1.92 | 3.89 | 58.35 | 57.24 | 3.13 | 4.89 | 0.3366 | 2.15 | 0.3198 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
| Jiangsu Cowin Biotech Co Ltd | 123.20m | -117.37m | 2.48bn | 657.00 | -- | 1.52 | -- | 20.11 | -1.12 | -1.12 | 1.21 | 14.49 | 0.0664 | 1.33 | 1.23 | 187,520.90 | -6.63 | -- | -6.94 | -- | 58.15 | -- | -99.82 | -- | 14.37 | -- | 0.0184 | -- | -67.15 | -- | -153.00 | -- | -- | -- |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 676.85m | 155.83m | 2.50bn | 738.00 | 15.96 | 2.04 | -- | 3.69 | 0.4781 | 0.4781 | 2.07 | 3.74 | 0.3666 | 1.92 | 11.71 | 917,147.40 | 8.40 | 12.01 | 10.14 | 14.75 | 63.88 | 69.79 | 22.92 | 22.84 | 1.21 | -- | 0.2589 | 36.44 | 2.54 | 4.24 | 0.8129 | 10.94 | -23.56 | 12.84 |
| Novoprotein Scientific Inc | 136.28m | -927.60k | 2.52bn | 579.00 | -- | 1.15 | -- | 18.50 | -0.0132 | -0.0132 | 1.94 | 31.19 | 0.0585 | 0.4493 | 1.67 | 235,364.30 | -0.0398 | -- | -0.0409 | -- | 70.17 | -- | -0.6807 | -- | 34.49 | -- | 0.0353 | -- | -42.09 | -- | -85.84 | -- | -- | -- |
| Ginwa Enterprise Group Inc | 572.93m | -23.61m | 2.52bn | 553.00 | -- | 1.56 | -- | 4.40 | -0.0633 | -0.0633 | 1.53 | 4.32 | 0.2988 | 4.74 | 5.64 | 1,036,046.00 | -1.23 | 0.3641 | -1.44 | 0.4141 | 75.60 | 73.64 | -4.12 | 1.15 | 3.33 | 0.3439 | 0.0206 | 124.25 | -2.41 | -5.37 | -228.19 | -- | 61.66 | -- |
Data as of May 31 2024. Currency figures normalised to Frontier Biotechnologies Inc's reporting currency: Chinese Yuan Renminbi CNY
8.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nuode Asset Management Co., Ltd.as of 21 Mar 2023 | 4.81m | 2.34% |
| UBS Asset Management Switzerland AGas of 21 Mar 2023 | 4.63m | 2.25% |
| China Asset Management Co., Ltd.as of 30 Sep 2022 | 2.80m | 1.36% |
| Da Cheng Fund Management Co., Ltd.as of 31 Dec 2023 | 1.16m | 0.57% |
| AEON Insurance Asset Management Co., Ltd.as of 21 Mar 2023 | 740.19k | 0.36% |
| Western Leadbank Fund Management Co., Ltdas of 31 Dec 2023 | 719.31k | 0.35% |
| SWS MU Fund Management Co., Ltd.as of 31 Dec 2023 | 719.22k | 0.35% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 383.19k | 0.19% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 315.00k | 0.15% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 228.11k | 0.11% |
More ▼
Data from 09 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
